抗炎三肽KdPT对小鼠眼干燥症的治疗作用
Therapeutic effect of anti-inflammatory tripeptide KdPT on ophthalmoxerosis in mice
-
摘要: 为探讨抗炎三肽KdPT治疗眼干燥症的疗效，用0.2%苯扎氯铵溶液处理8周龄雄性BALB/c小鼠，建立眼干燥症模型；造模4周后，将小鼠随机分为模型对照组，阳性对照组和KdPT的低、中、高剂量组。每组分别给予生理盐水、人工泪液和1、10、100 μg/mL KdPT。治疗3、5、7、10、14 d后，观察眼表面形态，进行荧光素钠染色评分；治疗14 d后用酚红棉线测定泪液分泌量；治疗14 d后处死动物取出右眼角膜进行组织病理学分析。实验结果显示，治疗3、5、7、10、14 d后，各组小鼠的状态和体重无明显异常。治疗14 d后，KdPT可促进泪液分泌，修复受损角膜上皮，对小鼠眼干燥症有显著治疗作用。KdPT有可能被开发为一种新型的眼干燥症治疗药物。Abstract: This study was designed to investigate the therapeutic effect of anti-inflammatory tripeptide KdPT on ophthalmoxerosis. Male BALB/c mice, 8-week old, were treated with 0.2% benzalkonium chloride solution to establish the ophthalmoxerosis model. Four weeks after modeling, the mice were randomly divided into control group, positive group and the low, medium, high dose groups of KdPT. Each group was given normal saline, artificial tears and 1, 10, 100 μg/mL KdPT, respectively. After 3, 5, 7, 10 and 14 days of treatment, the morphology of the eye surface was observed, and the fluorescein sodium staining score was performed. The amount of tear secretion was measured by phenol red cotton thread and the right corneas were taken out for histopathological analysis after 14 days of treatment. Data showed that there was no significant abnormality in general state and the weight of mice in each group at each time point of treatment. After 14 days of treatment, KdPT can promote the secretion of tear, repair the damaged corneal epithelium, and showed a significant therapeutic effect on ophthalmoxerosis in mice. Based on the data, it is possible for KdPT to be developed as a novel drug for ophthalmoxerosis.
-
Keywords:
- ophthalmoxerosis /
- tripeptide /
- KdPT /
- sodium fluorescein staining /
- tear secretion
-
-
[1] .Chin J Ophthalmol， 2013，49（1）： 73-75. [2] Liu ZG， Yang WZ. Dry eye and its pathogenesis［J］. Ophthalmol CHN. 2005，14（5）： 343-345. [3] Wei Y， Asbell PA. The core mechanism of dry eye disease is inflammation［J］. Eye Contact Lens， 2014， 40（4）： 248-256. [4] Yamaguchi T. Inflammatory response in dry eye［J］. Invest Ophthalmol Vis Sci， 2018， 59（14）： DES192-DES199. [5] Jung HH， Ji YS， Sung MS， et al. Long-term outcome of treatment with topical corticosteroids for severe dry eye associated with Sj?gren's syndrome［J］. Chonnam Med J， 2015， 51（1）： 26-32. [6] de Paiva CS， Pflugfelder SC， Ng SM， et al. Topical cyclosporine A therapy for dry eye syndrome［J］. Cochrane Database Syst Rev， 2019， 9： CD010051 .[7] Pavan J， Lukenda A， Stambuk N， et al. Effects of alpha-MSH on corneal epithelial lesions in rats［J］. Coll Antropol， 2012， 36（4）： 1407-1411. [8] Ru YS， Huang Y， Liu HJ， et al. Α-Melanocyte-stimulating hormone ameliorates ocular surface dysfunctions and lesions in a scopolamine-induced dry eye model via PKA-CREB and MEK-Erk pathways［J］. Sci Rep， 2015， 5： 18619. [9] Dou ZX， Ru YS， Liu HJ. Combinatorial protective effects of α-melanocyte-stimulating hormone and carboxymethylcellulose on ocular surface in dry eye rat model［J］. Chin J Exp Ophthalmol（中华实验眼科杂志），2017，35（6）： 498-505. [10] Bettenworth D， Buyse M， B?hm M， et al. The tripeptide KdPT protects from intestinal inflammation and maintains intestinal barrier function［J］. Am J Pathol， 2011， 179（3）： 1230-1242. [11] Kucharzik T， Lemmnitz G， Abels C， et al. Mo1216 tripeptide KdPT accelerates disease remission in patients with mild to moderate active ulcerative colitis［J］. Gastroenterology， 2014， 146（5）： S-588. [12] Li CJ， Ge H， Cui LJ， et al. Molecular mechanism of action of K（D）PT as an IL-1RI antagonist for the treatment of rhinitis［J］. RSC Adv， 2014，4（89）： 48741-48749. [13] Mykicki N， Klenner L， Baumann C， et al. The tripeptide KdPT ameliorates ongoing psoriasis-like skin inflammation in murine and human skin［J］. Exp Dermatol， 2017， 26（4）： 328-334. [14] Narayanan S， Corrales RM， Farley W， et al. Interleukin-1 receptor-1-deficient mice show attenuated production of ocular surface inflammatory cytokines in experimental dry eye［J］. Cornea， 2008， 27（7）： 811-817. [15] Yamada A， Arakaki R， Kudo Y， et al. Targeting IL-1 in Sj?gren's syndrome［J］. Expert Opin Ther Targets， 2013， 17（4）： 393-401. [16] Vijmasi T， Chen FY， Chen YT， et al. Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease［J］. Mol Vis， 2013， 19： 1957-1965.
计量
- 文章访问数: 146
- HTML全文浏览量: 10
- PDF下载量: 809
下载:
